G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a report issued on Thursday, Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright also issued estimates for G1 Therapeutics’ FY2026 earnings at $0.72 EPS.

A number of other brokerages have also recently issued reports on GTHX. Needham & Company LLC reiterated a buy rating and set a $12.00 target price on shares of G1 Therapeutics in a report on Wednesday, May 1st. Wedbush reissued an outperform rating and issued a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th.

G1 Therapeutics Price Performance

G1 Therapeutics stock opened at $4.49 on Thursday. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $5.00. The company has a debt-to-equity ratio of 1.34, a quick ratio of 3.45 and a current ratio of 2.94. The firm has a 50 day moving average price of $3.94 and a 200 day moving average price of $3.11. The company has a market cap of $234.74 million, a price-to-earnings ratio of -7.24 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The firm had revenue of $14.48 million during the quarter, compared to analysts’ expectations of $15.21 million. During the same period last year, the business posted ($0.53) earnings per share. Sell-side analysts predict that G1 Therapeutics will post -0.59 earnings per share for the current year.

Insider Buying and Selling

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.23% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On G1 Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FinTrust Capital Advisors LLC lifted its stake in shares of G1 Therapeutics by 154,946.2% in the fourth quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock worth $307,000 after acquiring an additional 100,715 shares in the last quarter. Capstone Investment Advisors LLC acquired a new position in shares of G1 Therapeutics in the 4th quarter valued at approximately $76,000. Financial Advocates Investment Management purchased a new position in shares of G1 Therapeutics during the 4th quarter valued at approximately $39,000. Jump Financial LLC acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth approximately $105,000. Finally, Choreo LLC bought a new stake in shares of G1 Therapeutics in the fourth quarter worth $107,000. 24.21% of the stock is owned by hedge funds and other institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.